We are live on ! Find out more
XDNA

Strategic Trust Kelly CRISPR & Gene Editing Technology ETF
XDNA

Delisted

XDNA was delisted on the 30th of November, 2023.

Back to rankings

2 hedge funds and large institutions have $281K invested in Strategic Trust Kelly CRISPR & Gene Editing Technology ETF in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding

Funds holding: 1 → 2 (+1)

70% less capital invested

Capital invested by funds: $943K → $281K (-$662K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
+1
Holders Change %
+100%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$1.57K

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$495K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
1
Jane Street
New York
$279K -$495K -47,691 -64%
UBS Group
2
UBS Group
Switzerland
$2K +$1.57K +151 New

XDNA Hedge Fund Activity: Q2 2022 in Review

2 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Strategic Trust Kelly CRISPR & Gene Editing Technology ETF (XDNA) for Q2 2022, worth a combined $281K — down 70% from $943K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new XDNA positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $1.57K. The largest seller was Jane Street, cutting an estimated $495K.

  • 2 institutional investors held Strategic Trust Kelly CRISPR & Gene Editing Technology ETF (XDNA) as of Q2 2022, up from 1 in Q1 2022.
  • Funds reported $281K of Strategic Trust Kelly CRISPR & Gene Editing Technology ETF stock for Q2 2022, down 70% quarter-over-quarter.
  • 1 fund opened new Strategic Trust Kelly CRISPR & Gene Editing Technology ETF positions in Q2 2022 and 0 closed out, a net change of +1 holder.
  • The largest Strategic Trust Kelly CRISPR & Gene Editing Technology ETF buyer in Q2 2022 was UBS Group, an estimated $1.57K added.
  • The largest Strategic Trust Kelly CRISPR & Gene Editing Technology ETF seller in Q2 2022 was Jane Street, an estimated $495K sold.

Based on aggregated 13F filings for Q2 2022.